Design and Setting: We conducted a case-cohort study within the Multi-Ethnic Study of Atherosclerosis. Participants with an incident CHD event over 12 years of follow-up (n = 538) and a randomly assigned subcohort (n = 999) were included. We measured baseline 25(OH)D, VDBG, and isoforms using mass spectrometry and estimated bioavailable 25(OH)D from published equations.
concentrations are associated with increased risk of coronary heart disease (CHD) across observational studies of predominantly white participants (1) (2) (3) (4) (5) (6) . 25(OH)D, which is the precursor of calcitriol, is the primary circulating form of vitamin D and the biomarker that is traditionally used to determine vitamin D deficiency or sufficiency states. Circulating 25(OH)D concentrations are substantially lower among black and Hispanic people but are not associated with CHD among these race and ethnicity groups (7) (8) (9) (10) (11) (12) (13) .
One possible explanation for the observed racial heterogeneity is differences in the amount of 25(OH)D that is available to bind to target tissues. The majority of circulating 25(OH)D is tightly bound to vitamin D binding globulin (VDBG), with a smaller amount (10% to 15%) loosely bound to albumin, and ,1% circulating in a free, unbound form (14, 15) . VDBG is a highly polymorphic gene; isoforms differ strongly by race and by affinity for 25(OH)D (16) . A recent study reported similar bioavailable 25(OH)D concentrations among whites and blacks, despite marked differences in total 25(OH)D (17) . However, subsequent studies have failed to replicate this finding when VDBG concentrations were measured using gold-standard liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods (18) (19) (20) (21) . Differences in VDBG and vitamin D availability may be critical to interpreting 25(OH)D concentrations and associated health outcomes, including differences by race and ethnicity.
We tested the hypothesis that VDBG concentration and isotype alter the association of 25(OH)D with CHD events in a community-based, multiracial and multiethnic study population. We measured serum VDBG concentrations, VDBG isotype, and 25(OH)D by using highly specific LC-MS/MS assays and evaluated associations with incident CHD events by race over long-term follow-up.
Methods

Study population
In the Multi-Ethnic Study of Atherosclerosis (MESA), 6814 community-dwelling adults between the ages of 45 and 84 years were recruited between July 2000 and August 2002 from six US communities: Baltimore City and Baltimore County, Maryland; Chicago, Illinois; Forsyth County, North Carolina; Los Angeles County, California; northern Manhattan and the Bronx, New York; and St. Paul, Minnesota (22) . MESA excluded patients who had prevalent clinical cardiovascular disease at baseline, defined as myocardial infarction, angina, stroke, transient ischemic attack, heart failure, atrial fibrillation, use of nitroglycerin, prior angioplasty, coronary artery bypass graft surgery, valve replacement, pacemaker or defibrillator implant, or any surgery on the heart or arteries. The cohort of participants is 38% non-Hispanic white, 28% African American, 22% Hispanic, and 12% Chinese American. The institutional review boards at all participating centers approved the study, and all participants gave written informed consent.
We selected participants for measurement of VDBG and albumin in 2015 by using a case-cohort design. Included were a random sample of MESA participants (subcohort, n = 999) and all those who had an incident CHD event by 31 December 2013 (cases, n = 538) (Fig. 1) . Incident CHD was defined as the first occurrence of any one of the following events during follow-up: acute myocardial infarction, death from CHD, resuscitated cardiac arrest, definite angina, or probable angina with coronary revascularization (23) . Participants with 25(OH)D concentrations .100 ng/mL (suggestive of high-dose supplementation) and participants without CHD follow-up data were excluded from analyses.
Measurement of exposures
VDBG concentration and isoform were measured simultaneously via an LC-MS/MS assay (18, 20) . This assay quantifies VDBG concentration by measuring the abundance of two VDBG peptide sequences that are conserved across VDBG isoforms, generating results that are not biased by VDBG genotype (a concern with commercially available antibody-based assays) (21, 24) . The assay uses internal standards to increase precision, with interassay coefficients of variation of 3.1% to 9.1% across a range of concentrations. At the same time, the assay detects the presence or absence of peptide sequences that define common VDBG isoforms, allowing direct determination of expressed isoforms (including multiple isoforms for heterozygotes). Isoform identification has previously been validated with genetic data (18) . Total 25(OH)D (sum of 25-hydroxyvitamins D 2 and D 3 ) was measured via high-performance LC-MS/MS (25) . Calibration was confirmed with National Institute of Standards and Technology standard reference material 972a (26) . Albumin was measured via the modified Doumas and Rodkey procedures on the Beckman-Coulter DxC. Bioavailable 25(OH)D concentrations were calculated via published equations allowing for six affinity coefficients based on VDBG isoforms (17, 27, 28 ). Analyses were repeated with bioavailable 25(OH)D calculated with a single binding coefficient and yielded similar results.
Measurement of covariates
Covariates were ascertained at the baseline MESA examination, concurrent with VDBG, albumin, and 25(OH)D. Participants completed self-administered questionnaires, interviewer-administered standardized interviews, and extensive inperson examinations, yielding demographic and lifestyle characteristics, medical history, anthropometric measurements, and laboratory data. Race and ethnicity were characterized based on participants' responses to questions modeled from the year 2000 US Census. General health was self-reported on a questionnaire as excellent, very good, good, fair, or poor. Leisure-time physical activity was estimated as the total amount of intentional exercise performed in a usual week and measured in metabolic equivalent task-minutes. Diabetes status was defined by the use of an oral hypoglycemic medication or insulin, fasting blood glucose $126 mg/dL, nonfasting blood glucose $200 mg/dL, or hemoglobin A1c $6.5% (29) . Body mass index was calculated as weight in kilograms divided by height in meters squared. Blood pressure was ascertained as the mean of the last two of three seated measurements. Total and high-density lipoprotein cholesterol were measured via the cholesterol oxidase method. Low-density lipoprotein cholesterol levels were calculated via the Friedewald equation. Intact serum parathyroid hormone (PTH) was quantified by a DxI automated two-site immunoassay on a clinical analyzer (Beckman-Coulter Inc, Brea, CA) (30) . Circulating fibroblast growth factor-23 (FGF-23) was measured in previously unthawed serum via the Kainos immunoassay, which detects the full-length, biologically intact FGF-23 molecule via midmolecule and distal epitopes. Urine albumin excretion was quantified as the ratio of albumin to creatinine in a single-voided urine sample. Serum calcium and phosphate were measured by indirect potentiometry on a DxC Synchron analyzer (Beckman-Coulter Inc) and timed-rate colorimetric reaction method, respectively (31) . Glomerular filtration rate was estimated from the creatinine-based Chronic Kidney Disease Epidemiology Collaboration equation (32) . Data on vitamin D supplement use were not available.
Statistical analysis
We examined baseline characteristics of the subcohort participants across tertiles of VDBG and bioavailable 25(OH)D concentrations; these were summarized with means and standard deviations, or medians and interquartile ranges for highly skewed variables. For the entire analysis population, we tabulated the number of CHD events overall and by race and ethnicity. We accounted for the small (,5%) amount of missing data by using multiple imputation with chained equations in all regression analyses (33); resulting estimates were combined according to Rubin's rules to account for the variability in the imputation procedure (34) .
In the primary analysis, we examined the associations of VDBG, total 25(OH)D, and bioavailable 25(OH)D concentrations with incident CHD in a series of Cox regression models with robust variance estimation that accounted for the casecohort study design, using the Prentice method (35-37). Participants were considered at risk from the date of their baseline MESA examination until the first occurrence of the composite outcome or until they were censored due to death from non-CHD cause (n = 160), loss to follow-up, or the end of available follow-up. The first model included adjustment for age, sex, race or ethnicity, MESA study site, income, and season. The second model further adjusted for additional potential confounders: diabetes, body mass index, smoking status, self-reported general health status, log-transformed intentional physical activity, estimated glomerular filtration rate, systolic blood pressure, use of antihypertensive medications, use of lipid-lowering medications, low-density lipoprotein cholesterol, C-reactive protein (CRP) (log-transformed) concentration, and serum albumin. When we examined the association of VDBG with incident CHD, a third model of potential mediators further adjusted for calcium, phosphorus, log-transformed PTH, log-transformed FGF-23, total 25(OH)D, and a total 25(OH)D by race or ethnicity interaction term.
When we examined the associations of total 25(OH)D with incident CHD, the third model further adjusted for VDBG concentration alone. To formally test differences in effect estimates from associations of total 25(OH)D with incident CHD before and after adjustment for VDBG, we calculated a confidence interval for the difference in b coefficients, by means of bootstrap methods (38) (2000 bootstraps for each of the 20 imputation datasets). Estimates were combined across imputations according to Rubin's rules.
Categorical covariates were modeled via indicator variables, except for self-reported health, which was modeled as a continuous term; continuous covariates were modeled linearly unless noted. Subgroup-specific hazard ratios (HRs) were calculated via linear combination of regression coefficients for (18) 44 (14) 56 (18) 68 (24) Baltimore and Baltimore County, Maryland 109 (12) 38 (12) 44 (14) 27 (9) St. Paul, Minnesota 159 (17) 48 (15) 49 (15) 
Results
VDBG concentrations and isoforms
At baseline, the mean [standard deviation (SD)] age in the subcohort was 59.4 (9.8) years, and 57% of participants were women. The measured VDBG isoform varied by race and ethnicity. The most common haplotype among white and Hispanic participants was Gc1s/Gc1s (41.8% and 31.7%, respectively) and among black and Chinese participants was Gc1f/Gc1f (58.5% and 35.1%, respectively). However, VDBG concentration did not vary substantially by race or ethnicity [mean (SD) in micrograms per milliliter: white, 250.9 (39.5); Chinese, 236.9 (29.2); black, 249.6 (37.5); and Hispanic, 251.4 (37.1)]. Gc2 and Gc1f haplotype carriage were associated with lower and higher concentrations of VDBG, respectively (Supplemental Table 1 ). Participants with higher VDBG concentrations were more likely to be female and to smoke and less likely to have diabetes, and they were characterized by higher serum concentrations of 25(OH)D, 1,25(OH)D, high-density lipoprotein, and CRP and lower physical activity levels ( Table 1) Table 2 ).
VDBG and CHD events Participants were followed for a median (interquartile range) of 12.4 (5.6-12.8) years. For incident CHD, the qualifying event was myocardial infarction for 204 participants, angina for 200 participants, resuscitated cardiac arrest for 16 participants, and CHD death for 88 participants. (Supplemental Table 3 ).
Participants with higher circulating concentrations of VDBG were more likely to experience a CHD event (fully adjusted HR, 1.78; 95% confidence interval, 1.46 to 2.14, per SD increment in VDBG concentration, P , 0.0001) ( Table 2 ). We did not observe HR heterogeneity in the association of VDBG and CHD by race or ethnicity (P for interaction = 0.59) ( Table 2) or by VDBG isoform (P for interaction = 0.86) (Supplemental Table 4 ). Secondary analyses that repeated the primary analysis with a more restrictive definition of incident CHD that included only incident myocardial infarction, CHD death, and resuscitated cardiac arrest yielded stronger results (Supplemental Table 5 ). Haplotype carriage was also associated with CHD events, but magnitudes of association appeared weaker than those of VDBG concentration (Supplemental Table 6 ).
25(OH)D and CHD events
Mean (SD) bioavailable 25(OH)D concentration was 4.6 (2.4) ng/mL and varied by race and ethnicity: 5.7 (2.5) ng/mL for white participants, 4.4 (1.9) ng/mL for Chinese participants, 2.5 (1.3) ng/mL for black participants, and 4.3 (1.9) ng/mL for Hispanic participants (P , 0.0001). Participants with high circulating bioavailable 25(OH)D were less likely to be female or diabetic, were more likely to have high income, better self-reported health, and high physical activity levels, and were characterized by low CRP and interleukin-6 (Supplemental Table 7 ).
Low circulating bioavailable 25(OH)D was associated with incident CHD events among white participants but not among black or Hispanic participants (Fig. 2 and Table 3 ). Results were not materially changed when bioavailable 25(OH)D was calculated assuming a single binding coefficient across all six isoforms.
Like bioavailable 25(OH)D, low circulating total 25(OH)D was associated with CHD events among white and Chinese participants. Associations of 25(OH)D with CHD were strengthened by additional adjustment for VDBG (Supplemental Table 8 
Discussion
In this multiethnic community-based cohort of adults without clinical cardiovascular disease at baseline, high circulating serum VDBG was strongly associated with increased risk of adjudicated incident CHD events. This association was strong, independent of known CHD risk factors, and consistent across race and ethnicity. Adjustment for VDBG strengthened associations of total 25(OH)D concentration with CHD events in white participants, and estimated bioavailable 25(OH)D was significantly associated with CHD events in whites. However, accounting for VDBG through adjustment or estimation of bioavailable 25(OH)D did not eliminate the racial and ethnic heterogeneity observed in 25(OH)D associations with CHD events, with null associations still present for black and Hispanic participants.
With the polyclonal enzyme-linked immunosorbent assay for VDBG, free and bioavailable 25(OH)D were more strongly associated with bone mineral density than total 25(OH)D (28), but VDBG was not associated with heart failure (40). One recent case-control study, which 4 ng/mL), and per SD increment for VDBG (SD = 38.8 mg/mL), from a race interaction model that adjusts for age, sex, race and ethnicity, study site, income, season, diabetes mellitus, body mass index, smoking status, self-reported general health status, logtransformed intentional physical activity, estimated glomerular filtration rate, systolic blood pressure, antihypertensive medications, lipid-lowering medications, low-density lipoprotein cholesterol, logtransformed CRP concentration, and serum albumin. Global P for interaction by race for each metabolite was 0.05 for total 25(OH)D, 0.45 for BAVD, and 0.58 for VDBG.
measured VDBG via the isoform-independent LC-MS/MS assay, found that higher VDBG concentrations were strongly associated with incident end-stage renal disease (41) . These associations are consistent in direction with our observed associations with incident CHD events. In contrast, among patients with liver failure, lower VDBG concentration is associated with in-hospital mortality, perhaps because it is a sign of severely impaired liver synthetic function in this setting (42) (43) (44) (45) .
The associations between VDBG and CHD may or may not be causal. VDBG is an acute phase reactant, and our noted associations could therefore reflect confounding by inflammation. However, adjustment for CRP, another acute phase reactant modestly correlated with VDBG, did not attenuate the associations. (46) . VDBG is the major protein responsible for the sequestration of G-actin monomers from plasma after tissue injury. Low concentrations of VDBG have been associated with worse survival among trauma patients (47, 48) . Circulating VDBG could also plausibly be related to CHD via other mechanisms, through modulation of inflammatory processes and innate immunity, and through binding of fatty acids as well as directly helping to regulate neutrophil, macrophage, fibroblast, and osteoclast activity (49) .
Previously, VDBG isoforms and concentrations measured by monoclonal immunoassay were reported to vary by race (17) . An important implication of this observation was that differences in VDBG may help explain racial variation in associations of total 25(OH)D concentration with health outcomes. However, subsequent (18, 20, 21) . Our data, generated via a mass spectrometry assay that is thought to quantify VDBG concentration without bias by race, ethnicity, or isoform, suggest that differences in VDBG do not explain racial or ethnic heterogeneity in associations of 25(OH)D with CHD and that alternative explanations should be sought. If the free and weakly bound portions of circulating 25(OH)D are most accessible to target tissues, accounting for VDBG could improve the precision of classifying 25(OH)D status and strengthen relationships with health outcomes. Indeed, free and bioavailable 25(OH)D were found to be more strongly associated with BMD than total 25(OH)D (50) among healthy young adults and more strongly associated with PTH and calcium among incident hemodialysis patients (27) . Consistent with these observations, we observed that adjustment for VDBG concentration substantially increased the magnitude of association of total 25(OH)D with CHD events among white and Chinese participants, and bioavailable 25(OH)D was strongly associated with CHD events among white participants. However, associations of bioavailable 25(OH)D with health outcomes should be interpreted with caution because they may be confounded by VDBG concentration, which we found to be strongly associated with both lower bioavailable 25(OH)D concentration and higher CHD risk. The finding of associations between the Gc2 and Gc1 haplotypes and incident CHD warrants investigation and replication.
Strengths of this study its racially and ethnically diverse, community-based population; the evaluation of incident events relevant to 25(OH)D and VDBG over a long period of longitudinal follow-up; the large number of observed events sampled in an efficient study design; and the use of state-of-the-art assays to measure 25(OH)D, VDBG, and isoform. As in any observational study, potential associations of VDBG and 25(OH)D with CHD events may be confounded by unmeasured factors that are associated with both mineral metabolism markers and CHD outcomes. However, confounding is minimized in MESA because, by design, participants were free of self-reported clinical cardiovascular disease at baseline and because potential confounding variables were quantified in a high-quality manner. An additional limitation is that our study may have limited power to detect associations of small magnitude within individual racial and ethnic groups and within individual VDBG isoforms.
Conclusions
Higher circulating VDBG concentrations are strongly associated with CHD events, and additional studies are warranted to determine the nature of this relationship. Incorporation of VDBG assessment strengthened existing associations of 25(OH)D with CHD events among white and Chinese participants, suggesting that accounting for VDBG may help classify health risks associated with low circulating 25(OH)D in these populations. However, associations of bioavailable 25(OH)D with health outcomes must be interpreted cautiously because they may be confounded by VDBG concentration. Moreover, neither VDBG concentrations nor genotype mitigated racial variation in the association of 25(OH)D with CHD, suggesting that explanations other than differences in VDBG should be sought for race and ethnicity heterogeneity in associations of 25(OH)D and CHD.
